Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731)

a Children's Oncology Group, multicentre, phase 3 trial

Howard M. Katzenstein, Max Langham, Marcio H. Malogolowkin, Mark D. Krailo, Alexander J. Towbin, Mary Beth McCarville, Milton J. Finegold, Sarangarajan Ranganathan, Stephen Dunn, Eugene D. McGahren, Gregory M. Tiao, Allison F. O'Neill, Muna Qayed, Wayne L. Furman, Caihong Xia, Carlos Rodriguez-Galindo, Rebecka L. Meyers

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4–6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy. Methods: In this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children <10 kg) intravenously over 6 h on day 1; fluorouracil (600 mg/m2 per dose or 20 mg/kg per dose for children <10 kg) intravenous push on day 2; and vincristine (1·5 mg/m2 per day to a maximum dose of 2 mg, or 0·05 mg/kg per day for children <10 kg) intravenous push on days 2, 9, and 16. The primary outcome was investigator-assessed event-free survival. As prespecified by protocol, we analysed the primary endpoint 6 years after enrolment (cutoff date June 30, 2017). This trial is registered with ClinicalTrials.gov, number NCT00980460, and is now permanently closed to accrual. Findings: Between May 18, 2010, and May 28, 2014, 51 patients in 32 centres in two countries were enrolled into the low-risk stratum of this trial, of whom 49 received c hemotherapy treatment after surgery and were evaluable for activity and safety. Median follow-up time for all evaluable patients was 42 months (IQR 36–62). 4-year event-free survival was 92% (95% CI 79–97) and 5-year event-free survival was 88% (72–95). Two (4%) of 49 patients had surgical complications (bile leaks). The most common grade 3–4 adverse events were febrile neutropenia in seven (14%) patients, decreased neutrophil count in three (6%) patients, infections in four (8%) patients, and diarrhoea in four (8%) patients. Ototoxicity occurred in one (2%) patient. One (2%) patient of the three who relapsed in this cohort died from disease. Two (4%) patients died in clinical remission after therapy discontinuation. One patient died of pneumonia and bacterial sepsis 1 year after therapy discontinuation and another patient died of unrelated causes 57 months after therapy completion. There were no treatment-related deaths. Interpretation: Minimal postoperative chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine can ensure disease control in patients with hepatoblastoma resected at diagnosis. Our results show that dose reduction of ototoxic agents is a safe, effective treatment for these children. Funding: National Institutes of Health

Original languageEnglish (US)
Pages (from-to)719-727
Number of pages9
JournalThe Lancet Oncology
Volume20
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Hepatoblastoma
Adjuvant Chemotherapy
Vincristine
Fluorouracil
Cisplatin
Disease-Free Survival
Fetal Proteins
Therapeutics
Histology
Bacterial Pneumonia
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731) : a Children's Oncology Group, multicentre, phase 3 trial. / Katzenstein, Howard M.; Langham, Max; Malogolowkin, Marcio H.; Krailo, Mark D.; Towbin, Alexander J.; McCarville, Mary Beth; Finegold, Milton J.; Ranganathan, Sarangarajan; Dunn, Stephen; McGahren, Eugene D.; Tiao, Gregory M.; O'Neill, Allison F.; Qayed, Muna; Furman, Wayne L.; Xia, Caihong; Rodriguez-Galindo, Carlos; Meyers, Rebecka L.

In: The Lancet Oncology, Vol. 20, No. 5, 01.05.2019, p. 719-727.

Research output: Contribution to journalArticle

Katzenstein, HM, Langham, M, Malogolowkin, MH, Krailo, MD, Towbin, AJ, McCarville, MB, Finegold, MJ, Ranganathan, S, Dunn, S, McGahren, ED, Tiao, GM, O'Neill, AF, Qayed, M, Furman, WL, Xia, C, Rodriguez-Galindo, C & Meyers, RL 2019, 'Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial', The Lancet Oncology, vol. 20, no. 5, pp. 719-727. https://doi.org/10.1016/S1470-2045(18)30895-7
Katzenstein, Howard M. ; Langham, Max ; Malogolowkin, Marcio H. ; Krailo, Mark D. ; Towbin, Alexander J. ; McCarville, Mary Beth ; Finegold, Milton J. ; Ranganathan, Sarangarajan ; Dunn, Stephen ; McGahren, Eugene D. ; Tiao, Gregory M. ; O'Neill, Allison F. ; Qayed, Muna ; Furman, Wayne L. ; Xia, Caihong ; Rodriguez-Galindo, Carlos ; Meyers, Rebecka L. / Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731) : a Children's Oncology Group, multicentre, phase 3 trial. In: The Lancet Oncology. 2019 ; Vol. 20, No. 5. pp. 719-727.
@article{fbf92308bcf74c14906bd3c6a2cb0ca3,
title = "Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial",
abstract = "Background: Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4–6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy. Methods: In this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100{\%} pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50{\%} Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children <10 kg) intravenously over 6 h on day 1; fluorouracil (600 mg/m2 per dose or 20 mg/kg per dose for children <10 kg) intravenous push on day 2; and vincristine (1·5 mg/m2 per day to a maximum dose of 2 mg, or 0·05 mg/kg per day for children <10 kg) intravenous push on days 2, 9, and 16. The primary outcome was investigator-assessed event-free survival. As prespecified by protocol, we analysed the primary endpoint 6 years after enrolment (cutoff date June 30, 2017). This trial is registered with ClinicalTrials.gov, number NCT00980460, and is now permanently closed to accrual. Findings: Between May 18, 2010, and May 28, 2014, 51 patients in 32 centres in two countries were enrolled into the low-risk stratum of this trial, of whom 49 received c hemotherapy treatment after surgery and were evaluable for activity and safety. Median follow-up time for all evaluable patients was 42 months (IQR 36–62). 4-year event-free survival was 92{\%} (95{\%} CI 79–97) and 5-year event-free survival was 88{\%} (72–95). Two (4{\%}) of 49 patients had surgical complications (bile leaks). The most common grade 3–4 adverse events were febrile neutropenia in seven (14{\%}) patients, decreased neutrophil count in three (6{\%}) patients, infections in four (8{\%}) patients, and diarrhoea in four (8{\%}) patients. Ototoxicity occurred in one (2{\%}) patient. One (2{\%}) patient of the three who relapsed in this cohort died from disease. Two (4{\%}) patients died in clinical remission after therapy discontinuation. One patient died of pneumonia and bacterial sepsis 1 year after therapy discontinuation and another patient died of unrelated causes 57 months after therapy completion. There were no treatment-related deaths. Interpretation: Minimal postoperative chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine can ensure disease control in patients with hepatoblastoma resected at diagnosis. Our results show that dose reduction of ototoxic agents is a safe, effective treatment for these children. Funding: National Institutes of Health",
author = "Katzenstein, {Howard M.} and Max Langham and Malogolowkin, {Marcio H.} and Krailo, {Mark D.} and Towbin, {Alexander J.} and McCarville, {Mary Beth} and Finegold, {Milton J.} and Sarangarajan Ranganathan and Stephen Dunn and McGahren, {Eugene D.} and Tiao, {Gregory M.} and O'Neill, {Allison F.} and Muna Qayed and Furman, {Wayne L.} and Caihong Xia and Carlos Rodriguez-Galindo and Meyers, {Rebecka L.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/S1470-2045(18)30895-7",
language = "English (US)",
volume = "20",
pages = "719--727",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731)

T2 - a Children's Oncology Group, multicentre, phase 3 trial

AU - Katzenstein, Howard M.

AU - Langham, Max

AU - Malogolowkin, Marcio H.

AU - Krailo, Mark D.

AU - Towbin, Alexander J.

AU - McCarville, Mary Beth

AU - Finegold, Milton J.

AU - Ranganathan, Sarangarajan

AU - Dunn, Stephen

AU - McGahren, Eugene D.

AU - Tiao, Gregory M.

AU - O'Neill, Allison F.

AU - Qayed, Muna

AU - Furman, Wayne L.

AU - Xia, Caihong

AU - Rodriguez-Galindo, Carlos

AU - Meyers, Rebecka L.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4–6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy. Methods: In this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children <10 kg) intravenously over 6 h on day 1; fluorouracil (600 mg/m2 per dose or 20 mg/kg per dose for children <10 kg) intravenous push on day 2; and vincristine (1·5 mg/m2 per day to a maximum dose of 2 mg, or 0·05 mg/kg per day for children <10 kg) intravenous push on days 2, 9, and 16. The primary outcome was investigator-assessed event-free survival. As prespecified by protocol, we analysed the primary endpoint 6 years after enrolment (cutoff date June 30, 2017). This trial is registered with ClinicalTrials.gov, number NCT00980460, and is now permanently closed to accrual. Findings: Between May 18, 2010, and May 28, 2014, 51 patients in 32 centres in two countries were enrolled into the low-risk stratum of this trial, of whom 49 received c hemotherapy treatment after surgery and were evaluable for activity and safety. Median follow-up time for all evaluable patients was 42 months (IQR 36–62). 4-year event-free survival was 92% (95% CI 79–97) and 5-year event-free survival was 88% (72–95). Two (4%) of 49 patients had surgical complications (bile leaks). The most common grade 3–4 adverse events were febrile neutropenia in seven (14%) patients, decreased neutrophil count in three (6%) patients, infections in four (8%) patients, and diarrhoea in four (8%) patients. Ototoxicity occurred in one (2%) patient. One (2%) patient of the three who relapsed in this cohort died from disease. Two (4%) patients died in clinical remission after therapy discontinuation. One patient died of pneumonia and bacterial sepsis 1 year after therapy discontinuation and another patient died of unrelated causes 57 months after therapy completion. There were no treatment-related deaths. Interpretation: Minimal postoperative chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine can ensure disease control in patients with hepatoblastoma resected at diagnosis. Our results show that dose reduction of ototoxic agents is a safe, effective treatment for these children. Funding: National Institutes of Health

AB - Background: Hepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4–6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy. Methods: In this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children <10 kg) intravenously over 6 h on day 1; fluorouracil (600 mg/m2 per dose or 20 mg/kg per dose for children <10 kg) intravenous push on day 2; and vincristine (1·5 mg/m2 per day to a maximum dose of 2 mg, or 0·05 mg/kg per day for children <10 kg) intravenous push on days 2, 9, and 16. The primary outcome was investigator-assessed event-free survival. As prespecified by protocol, we analysed the primary endpoint 6 years after enrolment (cutoff date June 30, 2017). This trial is registered with ClinicalTrials.gov, number NCT00980460, and is now permanently closed to accrual. Findings: Between May 18, 2010, and May 28, 2014, 51 patients in 32 centres in two countries were enrolled into the low-risk stratum of this trial, of whom 49 received c hemotherapy treatment after surgery and were evaluable for activity and safety. Median follow-up time for all evaluable patients was 42 months (IQR 36–62). 4-year event-free survival was 92% (95% CI 79–97) and 5-year event-free survival was 88% (72–95). Two (4%) of 49 patients had surgical complications (bile leaks). The most common grade 3–4 adverse events were febrile neutropenia in seven (14%) patients, decreased neutrophil count in three (6%) patients, infections in four (8%) patients, and diarrhoea in four (8%) patients. Ototoxicity occurred in one (2%) patient. One (2%) patient of the three who relapsed in this cohort died from disease. Two (4%) patients died in clinical remission after therapy discontinuation. One patient died of pneumonia and bacterial sepsis 1 year after therapy discontinuation and another patient died of unrelated causes 57 months after therapy completion. There were no treatment-related deaths. Interpretation: Minimal postoperative chemotherapy with two cycles of cisplatin, fluorouracil, and vincristine can ensure disease control in patients with hepatoblastoma resected at diagnosis. Our results show that dose reduction of ototoxic agents is a safe, effective treatment for these children. Funding: National Institutes of Health

UR - http://www.scopus.com/inward/record.url?scp=85064840268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064840268&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30895-7

DO - 10.1016/S1470-2045(18)30895-7

M3 - Article

VL - 20

SP - 719

EP - 727

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 5

ER -